Detection and Use of Nasal Nitrous Oxide and the Electronic Nose
NCT ID: NCT02476929
Last Updated: 2020-02-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
139 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-01-31
Study Completion Date
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Introduction: Rhinitis, sinonasal polyposis (SP) and asthma are diseases whose pathogenesis is based on inflammation. This will determine the presence of disease, its evolution and its treatment. It is therefore very important to develop and validate methodologies that allow us to noninvasively detect inflammation of the airways. Thus, just as exhaled nitric oxide (FeNO) has been studied as an important non-invasive marker of inflammation of the lower airways, nasal nitric oxide (nNO) may be a good marker of nasal inflammation. Furthermore, the electronic nose is an electronic nanosensor device capable of detecting specific volatile organic compounds (VOCs) that can be used as a non-invasive biomarker of biochemical processes in different diseases whose pathophysiology is also based on inflammation.
Objective: To determine reference values of nNO and different patterns of VOCs in healthy individuals, individuals with allergic rhinitis (AR) and non-allergic rhinitis and individuals with SP and asthma.
Methodology: Prospective, controlled study. Four groups will be included: Healthy subjects, patients with AR, non-allergic rhinitis and patients with SP and asthma (n=252). Prick-test to pneumoallergens will be performed. Determination of FeNO, nNO, lung function tests, measurement of VOCs by the electronic nose and blood samples will be taken. Bilateral nasal endoscopy and sample collection using the technique of brushing of mucosa and the placement of filter papers, for the study of nasal cytology and mediators of inflammation.
Objective: To determine reference values of nNO and different patterns of VOCs in healthy individuals, individuals with allergic rhinitis (AR) and non-allergic rhinitis and individuals with SP and asthma.
Methodology: Prospective, controlled study. Four groups will be included: Healthy subjects, patients with AR, non-allergic rhinitis and patients with SP and asthma (n=252). Prick-test to pneumoallergens will be performed. Determination of FeNO, nNO, lung function tests, measurement of VOCs by the electronic nose and blood samples will be taken. Bilateral nasal endoscopy and sample collection using the technique of brushing of mucosa and the placement of filter papers, for the study of nasal cytology and mediators of inflammation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ATP Project (Asthma afTer Polypectomy)
NCT02427503
Asthma
Nasal Polyps
COMPLETED
Proof of Concept of Remote Management of Chronic Inflammatory Airway Diseases for Patient Empowerment
NCT06217419
Chronic Rhinosinusitis With Nasal Polyps
Asthma
NOT_YET_RECRUITING
NA
Evaluation Effects of Nasal Nitric Oxide Measurements Are Associated With Atopy Status in Chronic Nasal Inflammation
NCT01295866
Hypersensitivity
Rhinitis
Respiratory Tract Diseases
+2 more
COMPLETED
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
NCT03963648
Chronic Rhinosinusitis (Diagnosis)
Nasal Polyps
Asthma
+4 more
UNKNOWN
NA
Nasal Obstruction Compared by Rhinomanometry and Nasal Inspiratory Peak Flow After Endoscopic Nasal Surgery
NCT05921396
Pituitary Adenoma Invasive
Nasal Obstruction
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Assessment of nasal and bronchial inflammation:
Rhinitis (allergic and non-allergic), SP and asthma are diseases that are characterized by processes whose pathogenesis is based on inflammation. Inflammation of the airways can be assessed directly or indirectly. The techniques for assessing inflammation directly can be divided into invasive techniques and non-invasive techniques.
Within invasive techniques we include those which require nasal or bronchial endoscopy such as biopsy. However, the applicability of these invasive methods has many limitations because they are not without risks and/or complications. They also require considerable experience to implement. It is therefore very important to develop and validate new methods that allow us to non-invasively detect inflammation of the upper and lower airways.
Nitrous oxide (NO): Is synthesized from the amino acid L-arginine by the action of the enzyme nitric oxide synthase (NOS). Three isoforms of this enzyme are known: nNOS or NOS1, which predominates in nervous tissue; iNOS, inducible NOS or NOS2, induced by an agent that activates the immune system; and eNOS, endothelial NOS or NOS3, constituent of the vascular endothelium. Since iNOS is found in different cells of the respiratory tract and is induced by various inflammatory cytokines, NO is considered to be an excellent marker for airway inflammation. Thus, just as exhaled nitric oxide (FeNO) is considered a good non-invasive marker of inflammation of the lower airways, nasal nitric oxide (nNO) potentially appears be a good marker of nasal inflammation.
Nasal nitric oxide (nNO): Some authors describe reference values for nNO up to one hundred times higher than those for FeNO. However, until now normal levels of nNO in different nasal diseases and in healthy individuals have not been established because the published results vary widely. Dotsch et al. in 1996 published a series of 67 healthy subjects in which they found mean nNO values in a healthy population of 96±47 ppb. A year later Ferguson studied 82 healthy patients and published mean normal values of nNO of 1197±361 ppb. Additional papers were published subsequently, but the results remained quite diverse.
As for the reference values in patients with rhinitis, data published so far are also contradictory. Some authors show that nNO is higher in patients diagnosed with rhinitis, especially in patients with AR. However, other studies have not observed differences in levels of nNO in patients diagnosed with rhinitis compared to the normal population.
The electronic nose: Is a new technique which is based on the detection of VOCs present in the gas phase of the human respiration and that can be detected by chromatography and mass spectrometry sensors. It consists of a device made up of several nanosensors that when exposed to volatile particles undergo specific changes in their electrical resistance, resulting in a pattern or profile of VOCs by logarithmic regression. These VOC patterns can be used as non-invasive biomarkers of several biochemical processes that occur in different diseases whose pathogenesis is based on inflammation. For example, in diseases of the airways they have been used successfully in comparing patterns of VOCs in patients with chronic obstructive pulmonary disease (COPD) and asthma. This technique's potential applicability in biomedicine is enormous.
In short, both measuring nNO and determining patterns of VOCs by the electronic nose are non-invasive methods that can help in the diagnosis and monitoring of certain respiratory diseases. However, in the case of nNO currently available studies show very different and conflicting results and in the case of the determination of VOCs by electronic nose there are very few papers published to date. It is therefore vital to design a study that allows us to clarify the potential utility of non-invasive markers of inflammation such as determination of nNO and determination of the different patterns of VOCs by electronic nose in healthy patients, in patients diagnosed with AR and non-allergic rhinitis and in patients with associated SP and asthma.
Working Hypothesis: Rhinitis, SP and asthma are prevalent diseases that cause considerable morbidity. Since the substrate of these diseases lies in inflammation, our group of investigators believe that the study of inflammation is one of the most interesting aspects for assessment and management of these diseases. Similarly to how measuring FeNO is being used as a good marker of bronchial inflammation, measuring nNO and determining patterns of VOCs by the electronic nose could also be two good non-invasive markers of upper and/or lower (in the case of VOCs) airway inflammation. However, although in recent years there have been some studies on the origin, function and utility of measuring nNO and the use of the electronic nose in respiratory disease, there are still many questions that remain in reference to these two techniques.
Rhinitis (allergic and non-allergic), SP and asthma are diseases that are characterized by processes whose pathogenesis is based on inflammation. Inflammation of the airways can be assessed directly or indirectly. The techniques for assessing inflammation directly can be divided into invasive techniques and non-invasive techniques.
Within invasive techniques we include those which require nasal or bronchial endoscopy such as biopsy. However, the applicability of these invasive methods has many limitations because they are not without risks and/or complications. They also require considerable experience to implement. It is therefore very important to develop and validate new methods that allow us to non-invasively detect inflammation of the upper and lower airways.
Nitrous oxide (NO): Is synthesized from the amino acid L-arginine by the action of the enzyme nitric oxide synthase (NOS). Three isoforms of this enzyme are known: nNOS or NOS1, which predominates in nervous tissue; iNOS, inducible NOS or NOS2, induced by an agent that activates the immune system; and eNOS, endothelial NOS or NOS3, constituent of the vascular endothelium. Since iNOS is found in different cells of the respiratory tract and is induced by various inflammatory cytokines, NO is considered to be an excellent marker for airway inflammation. Thus, just as exhaled nitric oxide (FeNO) is considered a good non-invasive marker of inflammation of the lower airways, nasal nitric oxide (nNO) potentially appears be a good marker of nasal inflammation.
Nasal nitric oxide (nNO): Some authors describe reference values for nNO up to one hundred times higher than those for FeNO. However, until now normal levels of nNO in different nasal diseases and in healthy individuals have not been established because the published results vary widely. Dotsch et al. in 1996 published a series of 67 healthy subjects in which they found mean nNO values in a healthy population of 96±47 ppb. A year later Ferguson studied 82 healthy patients and published mean normal values of nNO of 1197±361 ppb. Additional papers were published subsequently, but the results remained quite diverse.
As for the reference values in patients with rhinitis, data published so far are also contradictory. Some authors show that nNO is higher in patients diagnosed with rhinitis, especially in patients with AR. However, other studies have not observed differences in levels of nNO in patients diagnosed with rhinitis compared to the normal population.
The electronic nose: Is a new technique which is based on the detection of VOCs present in the gas phase of the human respiration and that can be detected by chromatography and mass spectrometry sensors. It consists of a device made up of several nanosensors that when exposed to volatile particles undergo specific changes in their electrical resistance, resulting in a pattern or profile of VOCs by logarithmic regression. These VOC patterns can be used as non-invasive biomarkers of several biochemical processes that occur in different diseases whose pathogenesis is based on inflammation. For example, in diseases of the airways they have been used successfully in comparing patterns of VOCs in patients with chronic obstructive pulmonary disease (COPD) and asthma. This technique's potential applicability in biomedicine is enormous.
In short, both measuring nNO and determining patterns of VOCs by the electronic nose are non-invasive methods that can help in the diagnosis and monitoring of certain respiratory diseases. However, in the case of nNO currently available studies show very different and conflicting results and in the case of the determination of VOCs by electronic nose there are very few papers published to date. It is therefore vital to design a study that allows us to clarify the potential utility of non-invasive markers of inflammation such as determination of nNO and determination of the different patterns of VOCs by electronic nose in healthy patients, in patients diagnosed with AR and non-allergic rhinitis and in patients with associated SP and asthma.
Working Hypothesis: Rhinitis, SP and asthma are prevalent diseases that cause considerable morbidity. Since the substrate of these diseases lies in inflammation, our group of investigators believe that the study of inflammation is one of the most interesting aspects for assessment and management of these diseases. Similarly to how measuring FeNO is being used as a good marker of bronchial inflammation, measuring nNO and determining patterns of VOCs by the electronic nose could also be two good non-invasive markers of upper and/or lower (in the case of VOCs) airway inflammation. However, although in recent years there have been some studies on the origin, function and utility of measuring nNO and the use of the electronic nose in respiratory disease, there are still many questions that remain in reference to these two techniques.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Allergic Rhinitis
Non-Allergic Rhinitis
Nasal Polyps
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nasal nitrous oxide
Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
Group Type
ACTIVE_COMPARATOR
Nasal nitrous oxide
Intervention Type
DEVICE
Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
Electronic nose
Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
Group Type
ACTIVE_COMPARATOR
Electronic nose
Intervention Type
DEVICE
To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasal nitrous oxide
Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
Intervention Type
DEVICE
Electronic nose
To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Sample of healthy individuals: Non-atopic individuals will be considered when skin prick skin tests with a standard battery of pneumoallergens are negative.
* Individuals with nasal endoscopy not showing inflammatory lesions or anatomic abnormalities and who have an acoustic rhinometry compatible with normal values.
* No sign of any acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals with Allergic Rhinitis: Atopic patients sensitized by skin prick testing and specific IgE determination to at least one perennial allergen.
* Patients with symptoms compatible with persistent moderate or severe AR as rated by the ARIA 2008 guide of at least two years of evolution.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals with non-allergic rhinitis: The subject will be considered non-atopic when skin prick skin tests with a standard battery of pneumoallergens are negative.
* Patients with symptoms of sneezing, watery rhinorrhea, nasal itching and/or nasal obstruction of at least two years evolution.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals diagnosed with Sinunasal Polyposis and asthma: Patients diagnosed with asthma by clinical and lung function tests.
* SP patients diagnosed by performing nasal endoscopy and CT of the paranasal sinuses.
* Could be non-atopic patients or present any concomitant allergic diseases.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
* Individuals with nasal endoscopy not showing inflammatory lesions or anatomic abnormalities and who have an acoustic rhinometry compatible with normal values.
* No sign of any acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals with Allergic Rhinitis: Atopic patients sensitized by skin prick testing and specific IgE determination to at least one perennial allergen.
* Patients with symptoms compatible with persistent moderate or severe AR as rated by the ARIA 2008 guide of at least two years of evolution.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals with non-allergic rhinitis: The subject will be considered non-atopic when skin prick skin tests with a standard battery of pneumoallergens are negative.
* Patients with symptoms of sneezing, watery rhinorrhea, nasal itching and/or nasal obstruction of at least two years evolution.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Sample of individuals diagnosed with Sinunasal Polyposis and asthma: Patients diagnosed with asthma by clinical and lung function tests.
* SP patients diagnosed by performing nasal endoscopy and CT of the paranasal sinuses.
* Could be non-atopic patients or present any concomitant allergic diseases.
* No acute infectious process during the four weeks preceding the study.
* Signed informed consent.
Exclusion Criteria
* Smoker with history of more than 10 pack-years.
* Pregnancy.
* Having been treated with nasal or systemic drugs that may alter nasal resistance (vasoconstrictors, anticholinergics, corticosteroids, antihistamines, immunosuppressants and/or immunomodulators) during the past three weeks.
* History of nasal surgery.
* Having an autoimmune or inflammatory systemic disease.
* Having an established diagnosis of intrinsic or extrinsic asthma (except polyposis group).
* Individuals with pathological nasal endoscopy.
* Suffering from a neoplastic disease.
* Having been treated with nasal or systemic drugs that may alter nasal resistance (vasoconstrictors, anticholinergics, corticosteroids, antihistamines, immunosuppressants and/or immunomodulators) during the past three weeks.
* Pregnancy.
* Having been treated with nasal or systemic drugs that may alter nasal resistance (vasoconstrictors, anticholinergics, corticosteroids, antihistamines, immunosuppressants and/or immunomodulators) during the past three weeks.
* History of nasal surgery.
* Having an autoimmune or inflammatory systemic disease.
* Having an established diagnosis of intrinsic or extrinsic asthma (except polyposis group).
* Individuals with pathological nasal endoscopy.
* Suffering from a neoplastic disease.
* Having been treated with nasal or systemic drugs that may alter nasal resistance (vasoconstrictors, anticholinergics, corticosteroids, antihistamines, immunosuppressants and/or immunomodulators) during the past three weeks.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitat Autonoma de Barcelona
OTHER
Sponsor Role
collaborator
Sociedad Española de Alergología e Inmunología Clínica
UNKNOWN
Sponsor Role
collaborator
Sociedad Española de Neumología y Cirugía Torácica
OTHER
Sponsor Role
collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorena Soto-Retes, physician
Role: PRINCIPAL_INVESTIGATOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lorena Soto-Retes
Barcelona, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, Bel EH, Sterk PJ. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007 Oct;120(4):856-62. doi: 10.1016/j.jaci.2007.05.043. Epub 2007 Jul 20.
Reference Type
BACKGROUND
Silkoff PE, Robbins RA, Gaston B, Lundberg JO, Townley RG. Endogenous nitric oxide in allergic airway disease. J Allergy Clin Immunol. 2000 Mar;105(3):438-48. doi: 10.1067/mai.2000.104938.
Reference Type
RESULT
Lundberg JO, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Anggaard A, Hokfelt T, Lundberg JM, Alving K. High nitric oxide production in human paranasal sinuses. Nat Med. 1995 Apr;1(4):370-3. doi: 10.1038/nm0495-370.
Reference Type
RESULT
Dotsch J, Demirakca S, Terbrack HG, Huls G, Rascher W, Kuhl PG. Airway nitric oxide in asthmatic children and patients with cystic fibrosis. Eur Respir J. 1996 Dec;9(12):2537-40. doi: 10.1183/09031936.96.09122537.
Reference Type
RESULT
Ferguson EA, Eccles R. Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Otolaryngol. 1997 Jul;117(4):614-7. doi: 10.3109/00016489709113447.
Reference Type
RESULT
Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol. 1997 Jan;99(1 Pt 1):58-64. doi: 10.1016/s0091-6749(97)70301-4.
Reference Type
RESULT
Arnal JF, Didier A, Rami J, M'Rini C, Charlet JP, Serrano E, Besombes JP. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy. 1997 Apr;27(4):358-62.
Reference Type
RESULT
Lewis NS. Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. Acc Chem Res. 2004 Sep;37(9):663-72. doi: 10.1021/ar030120m.
Reference Type
RESULT
Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1076-82. doi: 10.1164/rccm.200906-0939OC. Epub 2009 Aug 27.
Reference Type
RESULT
American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. doi: 10.1164/rccm.200406-710ST. No abstract available.
Reference Type
RESULT
Clement PA, Gordts F; Standardisation Committee on Objective Assessment of the Nasal Airway, IRS, and ERS. Consensus report on acoustic rhinometry and rhinomanometry. Rhinology. 2005 Sep;43(3):169-79.
Reference Type
RESULT
Serrano C, Valero A, Picado C. [Nasal nitric oxide]. Arch Bronconeumol. 2004 May;40(5):222-30. doi: 10.1016/s1579-2129(06)70088-x. No abstract available. Spanish.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIBSP-ONA-2011-146
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Electronic Nose Identification of Fasting and Non-fasting Breath Profiles
NCT02419976
TERMINATED
NA
Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis
NCT00939471
COMPLETED
NA
Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study
NCT01612780
COMPLETED
NA
Treatment of Chronic Frontal Sinusitis by a Simple Technique Using Dilation Balloons
NCT02509663
TERMINATED
NA
Nasal Findings in Reactive Airway Diseases
NCT03131323
UNKNOWN
Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps
NCT05009758
RECRUITING
NA
A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps
NCT00788463
COMPLETED
PHASE2
Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps
NCT04104594
TERMINATED
NA
The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype
NCT04171167
ACTIVE_NOT_RECRUITING
NA
Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage
NCT00292851
COMPLETED
Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children
NCT03336671
TERMINATED
NA
Nanoparticles in Nasal Mucosa
NCT02270125
COMPLETED
Using Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy
NCT06567821
RECRUITING
PHASE2/PHASE3
Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis
NCT02784262
COMPLETED
PHASE2
Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis
NCT05648565
COMPLETED
NA
SinuSys Patency of Frontal Recess and Sphenoid Sinus Ostia Study
NCT02463279
COMPLETED
NA
Posterior Nasal Nerve (PNN) Rhinitis Study
NCT03727347
COMPLETED
NA
Sinus Balloon Dilation in Pediatric Patients
NCT02278484
COMPLETED
NA
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
NCT00584662
TERMINATED
NA
Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis
NCT06264141
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Nasal Glucagon in Participants With a Common Cold
NCT02778100
COMPLETED
PHASE1
Real-Time Diagnosis of Eosinophilic Nasal Polyps Using High-Sensitivity Spectroscopy
NCT07125586
RECRUITING
NA
Comparison Between 4 Different Nasal Dilators
NCT02196389
TERMINATED
PHASE4
Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).
NCT07134686
NOT_YET_RECRUITING
NA
Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device
NCT04684875
COMPLETED